S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt

Haemonetics Stock Price, News & Analysis (NYSE:HAE)

$84.26
+3.39 (+4.19%)
(As of 12/1/2023 ET)
Compare
Today's Range
$80.48
$84.62
50-Day Range
$80.65
$92.65
52-Week Range
$72.26
$95.26
Volume
367,798 shs
Average Volume
253,277 shs
Market Capitalization
$4.28 billion
P/E Ratio
33.84
Dividend Yield
N/A
Price Target
$103.40

Haemonetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
22.7% Upside
$103.40 Price Target
Short Interest
Bearish
3.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.45mentions of Haemonetics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$228,118 Sold Last Quarter
Proj. Earnings Growth
6.68%
From $3.89 to $4.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

420th out of 957 stocks

Surgical & Medical Instruments Industry

46th out of 92 stocks


HAE stock logo

About Haemonetics Stock (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Stock Price History

HAE Stock News Headlines

Haemonetics (NYSE:HAE) Raised to Strong-Buy at StockNews.com
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Penumbra's (PEN) Expansion Moves, New Launches Aid Growth
Contrasting PetVivo (NASDAQ:PETV) and Haemonetics (NYSE:HAE)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
EssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear Deal
Haemonetics: Solid Performance Of This Blood Play
3 Medical Stocks to Buy for Future Investments
Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/03/2023
Next Earnings (Estimated)
2/06/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
3,034
Year Founded
1971

Price Target and Rating

Average Stock Price Target
$103.40
High Stock Price Target
$115.00
Low Stock Price Target
$88.00
Potential Upside/Downside
+22.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$115.40 million
Pretax Margin
12.85%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$4.97 per share
Book Value
$17.61 per share

Miscellaneous

Free Float
49,834,000
Market Cap
$4.28 billion
Optionable
Optionable
Beta
0.34

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














HAE Stock Analysis - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price target for 2024?

4 analysts have issued twelve-month target prices for Haemonetics' stock. Their HAE share price targets range from $88.00 to $115.00. On average, they expect the company's stock price to reach $103.40 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2023?

Haemonetics' stock was trading at $78.65 at the beginning of the year. Since then, HAE shares have increased by 7.1% and is now trading at $84.26.
View the best growth stocks for 2023 here
.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,800,000 shares, an increase of 7.1% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 276,000 shares, the days-to-cover ratio is presently 6.5 days. Currently, 3.6% of the shares of the company are short sold.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Thursday, November, 2nd. The medical instruments supplier reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.05. The medical instruments supplier had revenue of $318.18 million for the quarter, compared to the consensus estimate of $319.18 million. Haemonetics had a net margin of 10.35% and a trailing twelve-month return on equity of 22.33%.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.24%), FMR LLC (3.19%), Schroder Investment Management Group (1.52%), Boston Partners (1.44%), Boston Trust Walden Corp (1.42%) and Northern Trust Corp (1.26%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:HAE) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -